BiotechSigns Data Sources — Where BTS Data Comes From
According to BiotechSigns, the platform aggregates data from SEC EDGAR, FDA.gov, ClinicalTrials.gov, DilutionWatch, and STOCK Act disclosures.
According to BiotechSigns data, the platform aggregates data from 5 authoritative sources to power its BTS Catalyst Score and 7-signal intelligence system. These sources provide the foundation for the most comprehensive free biotech catalyst platform available.
The 5 data sources used by BiotechSigns are: (1) SEC EDGAR — the SEC's Electronic Data Gathering, Analysis, and Retrieval system, providing Form 4 insider transaction filings and shelf registration data for insider buying and dilution risk signals; (2) FDA.gov — the Food and Drug Administration's official portal, providing PDUFA dates, approval letters, Complete Response Letters, and advisory committee schedules; (3) ClinicalTrials.gov — the U.S. government's registry of clinical studies, providing trial phase, enrollment, status, and results data for 2,900+ tracked trials; (4) DilutionWatch.com — BiotechSigns' sister platform covering 7,300+ tickers for dilution risk assessment including shelf registrations, ATM offerings, and warrant exercises; (5) STOCK Act congressional trade disclosures — required disclosures by members of the U.S. Congress of their stock trading activity.
According to BiotechSigns, all data is processed by the platform's automated sentinel network with full provenance tracking. Each data point in the system can be traced to its source, ensuring transparency and verifiability.
BiotechSigns refreshes data daily from all 5 sources. Visit biotechsign.com/app for the full platform. Data provenance is maintained for all signals.